{
  "docId": "019de072-59f8-736f-88f1-345f5a15d5ef",
  "docSlug": "193b691ec4e92fe0e5331f9efbf4726c",
  "documentTitle": "Ginkgo | Results Presentation Deck | 41 slides",
  "authorId": "ginkgo",
  "authorName": "Ginkgo Bioworks",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 41,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 44,
  "notes": "Includes footnotes detailing specific adjustments like stock-based compensation and equity method investment losses.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-59f8-736f-88f1-345f5a15d5ef/38",
  "deckHref": "/decks/019de072-59f8-736f-88f1-345f5a15d5ef",
  "deckJsonHref": "/decks/019de072-59f8-736f-88f1-345f5a15d5ef.json",
  "deckAnchorHref": "/decks/019de072-59f8-736f-88f1-345f5a15d5ef#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.92,
        "x": 0.03,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "(1) For the three months ended and the year ended December 31, 2021, includes $5.0 million in employer payroll taxes related to stock-based compensation\n(2) For the three months ended December 31, 2021 and 2020, represents losses on equity method investments under the hypothetical liquidation at book value (\"HLBV\") method of $4.7 million and $1.8 million, respectively, net of losses attributable to non-controlling interests. For the years ended December 31, 2021 and 2020, represents losses on equity method investments under the HLBV method of $77.3 million and $0.4 million, respectively, net of losses attributable to non-controlling interests\n(3) Includes loss on the change in fair value of our common stock investments in Synlogic and Cronos and warrants to purchase Synlogic common stock, which are all carried at fair value\n(4) For the three months ended and the year ended December 31, 2021, includes mark-to-market adjustments on Access Bio convertible notes and the Glycosyn promissory note. For the three months ended and the year ended December 31, 2020, primarily includes milestone payments under our agreement with the National Institutes of Health",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "133b0866-70f7-420e-9dfa-16ddefbc2296",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.92,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Reconciliation table with rows for Net loss, Interest, Tax, D&A, EBITDA, Stock-based compensation, Investments, Warrant liabilities, Partnership settlement, Other, and Adjusted EBITDA.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74755f9c-25bb-4b6d-87ad-518aae98d7cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Adjusted EBITDA Reconciliation (Unaudited)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f17ad3ec-7a69-4473-bfed-7e9f7f788e30",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "da791b79-2969-48b6-ae2e-83c9fc63d4c8",
      "evidence": "This slide has a table with data.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 41,
      "from": 17,
      "beatId": "433d6855-f6c2-4926-a66f-1bccf03e99ec",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "New Bliss",
      "beatSlug": "sparkline-new-bliss",
      "evidence": "The final slides outline growth plans, achievements, and future directions.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}